Status:
COMPLETED
Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
Lead Sponsor:
University Hospital, Ghent
Conditions:
Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous administrations. As moxifloxacin is known to have a high oral bioavailability in healthy volunteers, patients a...
Eligibility Criteria
Inclusion
- IC patients treated with 400 mg moxifloxacin IV (once a day) that can be switched to enteral administration of 400 mg moxifloxacin.
- IV steady state
- Hemodynamic stability
- Normal enteral feeding without prokinetics
- Presence of arterial line
- Informed consent
- ≥ 18 jaar
Exclusion
- Dialysis patients
- Creatinine clearance \< 30 ml/min
- Transaminase levels \> 5x upper limit
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00458900
Start Date
July 1 2007
End Date
September 1 2012
Last Update
December 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, Belgium, 9000